Akebia Therapeutics (AKBA) Cash from Investing Activities Growth (1y) (2014 - 2026)
Akebia Therapeutics (AKBA) Cash from Investing Activities Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 13.93% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 57.14% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -186.78% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 551.55% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 526.11% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -3,664.79% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -3.45% |
| 10 | Akebia Therapeutics | 339.15 Mn | 176.55 Mn | 41.25 Mn | -140.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -140.26% |
| Dec 31, 2025 | -393,750.00% |
| Sep 30, 2025 | -3,750.00% |
| Jun 30, 2025 | -334.48% |
| Mar 31, 2022 | -100.57% |
| Jun 30, 2021 | 140.00% |
| Mar 31, 2021 | 8,039.18% |
| Dec 31, 2020 | 167.88% |
| Sep 30, 2020 | -304.74% |
| Jun 30, 2020 | -192.53% |
| Mar 31, 2020 | -99.78% |
| Dec 31, 2019 | 33.28% |
| Sep 30, 2019 | 121.51% |
| Jun 30, 2019 | 1,614.38% |
| Mar 31, 2019 | 788.48% |
| Dec 31, 2018 | 301.22% |
| Sep 30, 2018 | 124.49% |
| Jun 30, 2018 | 88.74% |
| Mar 31, 2018 | 113.47% |
| Dec 31, 2017 | -137.25% |